Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 2/2019

01-02-2019 | Letter to the Editor

The world’s first clinical trial for an aplastic anemia patient with thrombocytopenia administering platelets generated from autologous iPS cells

Authors: Akira Akabayashi, Eisuke Nakazawa, Nancy S. Jecker

Published in: International Journal of Hematology | Issue 2/2019

Login to get access

Excerpt

On September 21, 2018, the Japanese Ministry of Health, Labor and Welfare announced it had approved a plan for the first-ever use of an experimental therapy on a patient with aplastic anemia and thrombocytopenia, which will involve the infusion of platelets generated from an autologous induced pluripotent stem cells (iPSCs). The patient had a history of rejection reactions to allogeneic platelets. …
Literature
1.
Nature Editorials. Racing hearts. Japan must show that a promising therapy for damaged hearts works as claimed. Week Nat. 2018;557:611–2.
2.
3.
Metadata
Title
The world’s first clinical trial for an aplastic anemia patient with thrombocytopenia administering platelets generated from autologous iPS cells
Authors
Akira Akabayashi
Eisuke Nakazawa
Nancy S. Jecker
Publication date
01-02-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-02565-y

Other articles of this Issue 2/2019

International Journal of Hematology 2/2019 Go to the issue

Original Article

Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study

Case Report

A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis

Correction

Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan

Original Article

Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation

Case Report

Epstein–Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution

Guide Line

JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits